Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

Tumor necrosis factor-α (TNFα) was cloned over 2 decades ago and its identification in part
led to the discovery of a super family of tumor necrosis factors (TNFs) and their receptors …

Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …

Background We did a randomised controlled trial to assess the benefit of maintenance
infliximab therapy in patients with active Crohn's disease who respond to a single infusion of …

Rheumatoid arthritis is a common chronic inflammatory and destructive arthropathy that
cannot be cured and that has substantial personal, social, and economic costs. The long …

Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear
and consensual international recommendations on RA treatment are not available. In this …

Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …

TNF was originally described as a circulating factor that can cause necrosis of tumours, but
has since been identified as a key regulator of the inflammatory response. This review …

ContextTumor necrosis factor (TNF) plays an important role in host defense and tumor
growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious …

Background Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor
necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the …